Preclinical services

Neuro-Sys has developed specific preclinical in vitro models of CNS and PNS diseases to achieve high-quality efficacy pharmacology as well as mode of action studies, a unique cost-effective strategy to accurately determine the pharmacological profiling of lead compounds and explore their underlying mechanism of action. We provide studies to determine the neuroprotective activity of lead compounds but also of dietary supplements and medical nutrition.
We are dedicated to providing high-level technical expertise and preclinical CRO services in a collaborative relationship with our clients, mainly focusing on :

› Alzheimer’s disease (AD)
› Parkinson’s disease (PD)
› Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease)
› Multiple Sclerosis (MS)
› Peripheral Neuropathies

NEURO-SYS HAS BEEN AWARDED "BEST INTERNATIONAL DRUG DEVELOPMENT AND DISCOVERY DEVELOPMENT COMPANY, 2019" BY GHP !